Background: The clinical development program of extrafine single-inhaler triple therapy (efSITT) consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) in asthma excluded patients with concomitant COPD. TriMaximize provides first real-world evidence of efSITT's impact on asthma control in asthma patients with concomitant COPD. Aims and objectives: The aim of this international observational study is to gain insights into treatment pathways, asthma control and health-related outcomes in moderate-to-severe asthma patients after switching to efSITT in a period of 12 to 36 months. Methods: This interim analysis, after three months of treatment with BDP/FF/G (87/5/9 µg), includes 317 patients. The level of asthma control in patients with asthma and concomitant COPD (n=82) was compared with the remaining asthma patients irrespective of other comorbidities (n=235). The asthma control was measured by the Asthma Control Test (ACT). Results: In total, 26% of the included patients had concomitant COPD. The mean ACT score at baseline was 13.1 points (pts) in the group with concomitant COPD and 14.7 pts in asthma only group. After 3 months of treatment with efSITT, the ACT score improved 3.3 pts in the overall population, and 4.4 pts and 2.9 pts in the asthma-COPD and asthma only group, respectively (all p<0.0001). Conclusions: Significant improvement in asthma control was observed in asthma patients including those with concomitant COPD after three months of treatment with efSITT. These results contribute to bridge the gap between the findings from clinical trials and routine practice.